Role of O6-methylguanine-DNA methyltransferase in the resistance of pancreatic tumors to DNA alkylating agents

Cancer Research

Volumn 57, Issue 23, 1997, Pages 5360-5368

  Kokkinakis, Demetrius M ^a,c   Ahmed, Mansoor M ^b   Delgado, Ruby ^a   Fruitwala, Mushdaq M ^b   Mohiuddin, Mohammed ^b   Albores Saavedra, Jorge ^a  

^a UNIVERSITY OF TEXAS AT DALLAS   (United States)

^b UNIVERSITY OF KENTUCKY   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

6 O METHYLGUANINE; ALKYLATING AGENT; DNA METHYLTRANSFERASE; CARMUSTINE; LOMUSTINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; STREPTOZOCIN;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER SURVIVAL; DNA ALKYLATION; DNA DAMAGE; GENETIC STABILITY; GENOTOXICITY; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; PANCREAS TUMOR; PRIORITY JOURNAL; ADENOCARCINOMA; ADULT; AGED; APOPTOSIS; BIOSYNTHESIS; CANCER STAGING; CELL CULTURE; CELL SURVIVAL; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; FEMALE; MALE; METABOLISM; MIDDLE AGED; MITOSIS; PATHOLOGY; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CARMUSTINE; CELL SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LOMUSTINE; MALE; MIDDLE AGED; MITOSIS; NEOPLASM STAGING; O(6)-METHYLGUANINE-DNA METHYLTRANSFERASE; PANCREATIC NEOPLASMS; STREPTOZOCIN; SURVIVAL RATE; TUMOR CELLS, CULTURED;

EID: 0030609010     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (66)

1. Parker, S. L., Tong, T., Bolden, S., and Wingo, P. A. Cancer statistics, 1995. Cancer (Phila.), 46: 5-27, 1995.
2. Hunstad, D. A., and Norton, J. A. Management of pancreatic carcinoma. Surg. Oncol., 4: 61-74, 1995.
3. Janes, R. H., Jr., Niederhuber, J. E., Chmiel, J. S., Winchester, D. P., Ocwieja, K. C., Karnell, J. H., Clive, R. E., and Menck, H. R., National patterns of care for pancreatic cancer: results of a survey by the Commission on Cancer. Ann. Surg., 223: 261-272, 1996.
4. Perilli, D., Mansi, C., Savarino, V., and Celle, G. Hormonal therapy of pancreatic carcinoma: rationale and perspectives. Int. J. Pancreatol., 13: 159-168, 1993.
5. Wanebo, H. J., and Vezeridis, M. P. Pancreatic carcinoma in perspective: a continuing challenge. Cancer (Phila.), 78: 580-591, 1996.
6. Lionetto, R., Pugliese, V., Bruzzi, P., and Rosso, R. No standard treatment is available for advanced pancreatic cancer. Eur. J. Cancer., 31A: 867-869, 1995.
7. Casper, E. S., Green, M. R., Kelsen, D. P., Heelan, R. T., Brown, T. D., Flombaum, C. D., Trochanowski, B., and Tarassoff, P. G. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest. New Drugs, 12: 29-34, 1994.
8. Ettinghausen, S. E., Schwartzentruber, D. J., and Sindelar, W. F. Evolving strategies for the treatment of adenocarcinoma of the pancreas: a review. J. Clin. Gastroenterol., 21: 48-60, 1995.
9. Douglass, H. O., Jr. Adjuvant therapy for pancreatic cancer. World J. Surg., 19: 270-274, 1995.
10. Cornelison, T. L., Goldberg, J. M., and Piver, M. S. Taxol and platinum chemotherapy in the treatment of pancreatic and jejunal carcinoma. J. Surg. Oncol., 59: 204-208, 1995.
11. Gall, F. P., and Kockerling, F. The problem of radical surgery in pancreatic cancer and its implications for a combined treatment approach. Recent Results Cancer Res., 110: 79-86, 1988.
12. Cubilla, A. L., Fortner, J., and Fitzgerald, P. J. Lymph node involvement in carcinoma of the head of the pancreas. Cancer (Phila.), 41: 880-887, 1978.
13. Nagakawa, T., Kobayashi, H., Ueno, K., Ohta, T., Kayahara, M., and Miyazaki, I. Clinical study of the lymphatic flow to the paraaortic lymph nodes in carcinoma of the head of the pancreas. Cancer (Phila.), 73: 1155-1162, 1994.
14. Moore, M. Activity of gemcitabine in patients with advanced pancreatic carcinoma: a review. Cancer (Phila.), 78: 633-638, 1996.
15. Ahlgren, J. D. Chemotherapy for pancreatic carcinoma: a review. Cancer (Phila.), 78: 654-663, 1996.
16. Oster, M. W., Gray, R., Panasci, L., and Perry, M. C. Chemotherapy for advanced pancreatic cancer: a comparison of FAM with FSM. Cancer (Phila.), 57: 29-33, 1986.
17. Kelsen, D., Hudis, C., Niedzwiecki, D., Dougherty, J., Casper, E., Botet, J. Vinciquerra, V., and Rosenbluth, R. A phase III comparison trial of streptozotocin, mitomycin, and 5-FU with cisplatin, 1-β-D-arabinofuranosylcytosine, and caffeine in patients with advanced pancreatic carcinoma. Cancer (Phila.), 68 (Suppl. 5): 965-969, 1991.
18. Cullinan, S., Moertel, C. G., Wieand, H. S., Schutt, A. J., Krook, J. E., Foley, J. F., Norris, B. D., Kardinal, C. G., Tschetter, L. K., and Barlow, J. F. A phase III trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-FU, doxorubicin, and cisplatin. Cancer (Phila.), 65: 2207-2212, 1990.
19. Frey, C., Twomey, R., Keehn, R., Elliott, D., and Higgins, G. Randomized study of 5-FU and CCNU in pancreatic cancer: report of the Veterans Administration Surgical Adjuvant Cancer Chemotherapy Study Group. Cancer (Phila.), 47: 27-31, 1981.
20. GITSG. Phase II studies of drug combination in advanced pancreatic carcinoma. J. Clin. Oncol., 4: 1794-1799, 1986.
21. Horton, J., Gelber, R., Engstrom, P., Falkson, G., Moertel, C., Brodovsky, H., and Douglass, H. Trials of single-agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treat. Rep., 65: 65-68, 1981.
22. Bukowski, R. M., Balcerzak S. P., O'Bryan, R. M., Bonnet, J., and Chen, T. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer: a Southwest Oncology Group Study. Cancer (Phila.), 52: 1577-1582, 1983.
23. Carmichael, J., Fink, U., Russell, R., Spittle, M., Harris, A. L., Spiessi, G., and Blatter, J. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br. J. Cancer, 73: 101-105, 1996.
24. Holm, P. S., Scanlon, K. J., and Dietel, M. Reversion of multidrug resistance in the P-glycoprotein-positive human pancreatic cell line (EPP85-181RDB) by introduction of a hammerhead ribozyme. Br. J. Cancer, 70: 239-243, 1994.
25. Abrams, R. A., and Grochow, L. B. Adjuvant therapy with chemotherapy and radiation therapy in the management of carcinoma of the pancreatic head. Surg. Clin. North Am., 75: 925-938, 1995.
26. Brent, T. P. Suppression of cross-link formation in chloroethylnitrosourea-treated DNA by an activity in extracts of human leukemic lymphoblasts. Cancer Res., 44: 1887-1892, 1984.
27. 6-alkylguanine-DNA alkyltransferase and sensitivity to procarbazine in human brain-tumor xenografts. J Neurosurg., 70: 573-577, 1989.
28. 6-methylguanine-DNA methyltransferase. Oncol. Res., 5: 83-86, 1993.
29. 6-alkylguanine in cell killing and mutagenesis in Chinese hamster ovary cells. Carcinogenesis (Lond.), 12: 83-89, 1991.
30. 6-benzylguanine with or without streptozotocin enhances 1,3-bis(2-chloroethyl)-1-nitrosourea sensitivity in vitro. Cancer Res., 53: 4281-4286, 1993.
31. 6-benzylguanine in vitro. Carcinogenesis (Lond.), 14: 1057-1060, 1993.
32. 6-methylguanine-DNA methyltransferase activity in two human lung cancer cell lines. Eur. J. Cancer, 27: 1658-1662, 1991.
33. 6-alkyl-guanine-DNA alkyltransferase and glutathione to modulate nitrosourea resistance in breast cancer. Biochem. Pharmacol., 48: 543-548, 1994.
34. 6-benzylguanine and hypoxia on the cytotoxicity of 1,3-bis(2-chloroethyl)-1-nitrosourea in nitrosourea-resistant SF-763 cells. Cancer Chemother. Pharmacol., 32: 477-481, 1993.
35. 6-Methylguanine DNA methyltransferase activity and sensitivity of human tumor cell lines to bis-chloroethyl nitrosourea. Chin. Med. Sci. J., 7: 187-190, 1992.
36. 6-alkylguanine-DNA alkyltransferase: regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Res., 50: 6119-6129, 1990.
37. 6-alkylguanine-DNA alkyltransferase. Prog. Nucleic Acid Res. Mol. Biol., 51: 167-223, 1995.
38. 6-alkylguanine-DNA-alkyltransferase purified from human leukemic lymphoblasts. Cancer Res., 47: 3384-3387, 1987.
39. 6-benzylguanine. Biochemistry, 32: 11998-12006, 1993.
40. 6-methylguanine. Carcinogenesis (Lond.), 12: 2305-2309, 1991.
41. 6-benzylguanine analogues on sensitivity of human tumor cells to the cytotoxic effects of alkylating agents. Cancer Res., 51: 3367-3372, 1991.
42. 6-alkylguanine-DNA alkyltransferase. J. Cancer Res. Clin. Oncol., 121: 225-229, 1995.
43. 6-methylguanine-DNA methyltransferase by methionine in human tumour cells. Br. J. Cancer, 75: 779-788, 1997.
44. Ayi, T. C., Loh, K. C., Ali, R. B., and Li, B. F. Intracellular localization of human DNA repair enzyme methylguanine-DNA methyltransferase by antibodies and its importance. Cancer Res., 52: 6423-6430, 1992.
45. 6-methylguanine-DNA methyltransferase. Oncol. Res., 5: 83-86, 1993.
46. 6-alkylguanine DNA-alkyltransferase in human liver and melanoma. Br. J. Cancer, 66: 355-360, 1992.
47. Ishibashi, T., Nakabeppu, Y., Kawate, H., Sakumi, K., Hayakawa, H., and Sekiguchi, M. Intracellular localization and function of DNA repair methyltransferase in human cells. Mutat. Res., 315: 199-212, 1994.
48. Ishibashi, T., Nakabeppu, H., and Sekiguchi, M. Artificial control of nuclear translocation of DNA repair methyltransferase. J. Biol. Chem., 269: 7645-7650, 1994.
49. 6-methylguanine acceptor protein in extracts of human breast-tumor tissues. Cancer Biochem. Biophys., 12: 53-58, 1991.
50. 6-Methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis (Lond.), 13: 1503-1507, 1992.
51. 6-benzylguanine or N-methyl-N′-nitro-N-nitrosoguanidine. Carcinogenesis (Lond.), 12: 1679-1683, 1991.
52. 6-methylguanine-DNA methyltransferase in human tumor and corresponding normal tissue. Cancer Detect. Prev., 20: 130-136, 1996.
53. 6-Methylguanine-DNA methyltransferase activity in breast and brain tumors. Int. J. Cancer, 61: 321-326, 1995.
54. 6-Methylguanine-DNA methyltransferase in human normal and tumor tissue from brain, lung, and ovary. Cancer Res., 51: 4131-4134, 1991.
55. 6-Methylguanine-DNA methyltransferase activity in human tumors. Carcinogenesis (Lond.), 13: 1503-1507, 1992.
56. 6-Methyltransferase activity in human liver tumors. Carcinogenesis (Lond.), 12: 1313-1317, 1991.
57. 6-Methylguanine-DNA methyltransferase in normal and malignant tissue of the breast. Cancer Invest., 12: 605-610, 1994.
58. Liu, L. L., Markowitz, S., and Gerson, S. L. Mismatch repair mutations override alkyltransferase in conferring resistance to temozolomide but not to 1,3-bis(2-chloroethyl)nitrosourea. Cancer Res., 56: 5375-5379, 1996.
59. Karran, P., and Bignami, M. DNA damage tolerance, mismatch repair and genome instability. BioEssays, 16: 833-839, 1994.
60. Anthoney, D. A., McIlwrath, A. J., Gallagher, W. M., Edlin, A. R. M., and Brown, R. Microsatellite instability, apoptosis, and loss of p53 function in drug-resistant tumor cells. Cancer Res., 56: 1374-1381, 1996.
61. Kat, A., Thilly, W. G., Fang, W., Longley, M. J., Li, G., and Modrich, P. An alkylating-tolerant, mutator human cell line is deficient in strand-specific mismatch repair. Proc. Natl. Acad. Sci. USA, 90: 6424-6428, 1993.
62. Aquilina, G., Hess, P., Branch, P., MacGeoch, C., Casciano, I., Karran, P., and Bignami, M. A mismatch recognition defect in colon carcinoma confers DNA microsatellite instability and a mutator phenotype. Proc. Natl. Acad. Sci. USA, 91: 8905-8909, 1994.
63. Branch, P., Aquilina, G., Bignami, M., and Karran, P. Defective mismatch binding and a mutator phenotype in cells tolerant to DNA damage. Nature (Lond.), 362: 652-654, 1993.
64. Reed, M., Woelker, B., Wang, P, Wang, Y., Anderson, M. E., and Tegtmeyer, P. The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. Proc. Natl. Acad. Sci. USA, 92: 9455-9459, 1995.
65. Lee, S., Elenbaas, B., Levine, A., and Griffith, J. p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. Cell, 81: 1013-1020, 1995.
66. Venkatasubbarao, K., Ahmed, M. M., Swiderski, C., Harp, C., Mattingly, C., Fruitwala, S., Lee, E., Strodel, W., Mohiuddin, M., and Freeman, J. W. Microsatellite instability and mutational status of transforming growth factor-β type II receptor gene in pancreatic adenocarcinoma. Proc. Am. Assoc. Cancer Res., 38: 149, 1997.